Appeal No. 1997-3019
Application No. 08/404,122
This is an appeal under 35 U.S.C. § 134 from the final rejection of claims 1 through
8, 10 and 11, all the claims remaining in the application.
Claims 1, 4, 10 and 11 are representative of the subject matter on appeal:
1. A vaccine formulation comprising an antigenic component and, as an adjuvant
component, neuraminidase and galactose oxidase.
4. A formulation according to claim 1, in which the ratio of neuraminidase to
galactose oxidase in terms of units of activity is from 1:2 to 1:10.
10. A vaccine adjuvant comprising neuraminidase and galactose oxidase.
11. A method of inducing immunity in a patient comprising administering to said
patient said vaccine formulation according to claim 1 in an amount sufficient to induce said
immunity.
The references relied upon by the examiner are:
Knop et al. (Knop) 4,510,129 Apr. 9, 1985
UK Patent Spec. 1,569,003 Jun. 11, 1980
Lipkowitz et al. (Lipkowitz), “Cellular and Growth Factor Requirements for Activation of
Human T Lymphocytes by Neuraminidase and Galactose Oxidase-Treated Lymphoid
Cells,” Journal of Immunology, Vol. 130, No. 6, pp. 2702-2707 (June 1983)
Roitt et al. (Roitt), “Figure 8.8, Overview of the Immune Response,” in Immunology, Gower
Medical Publishing, New York, p. 8.3 (1985)
Rhodes, “Evidence for an Intercellular Covalent Reaction Essential in Antigen-Specific T Cell
Activation,” Journal of Immunology, Vol. 143, No. 5, pp. 1482-1489 (September 1,1989)
Sigma Chemical Company Catalog, “Galactose Oxidase,” p. 630 (1989)
Ada, “Modern Vaccines - The Immunological Principles of Vaccination,” The Lancet, Vol. 335,
pp. 523-526 (March 3, 1990)
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 Next
Last modified: November 3, 2007